Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Elucidating the Role of Tolerogenic Dendritic Cells in Immune Tolerance and Disease Progression in Multiple Myeloma

Mariko Ishibashi, Mika Sunakawa-Kii, Hiroki Yamaguchi, Rimpei Morita, Hideto Tamura

Blood (2023) 142 (Supplement 1): 6596.

https://doi.org/10.1182/blood-2023-179078

Published: 2023

Journal Articles

DNAM-1/Tigit/CD155/CD112 Axis Is a Novel Target of NK-Cell Therapy in Acute Myeloid Leukemia

Yuta Kaito, Emi Sugimoto, Fumi Nakamura, Yutaka Tsukune, Makoto Sasaki, Shunsuke Yui, Hiroki Yamaguchi, Susumu Goyama, Yasuhito Nannya, Kinuko Mitani, Hideto Tamura, Yoichi Imai

Blood (2022) 140 (Supplement 1): 4514–4516.

https://doi.org/10.1182/blood-2022-164435

Published: 2022

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

Mariko Ishibashi, PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Hiroshi Handa, MD PhD, Koiti Inokuchi, MD PhD, Hidemi Takahashi, MD PhD, Hideto Tamura, MD PhD

Blood (2018) 132 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2018-99-112322

Published: 2018

Journal Articles

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Blood (2018) 132 (Supplement 1): 5320.

https://doi.org/10.1182/blood-2018-99-111649

Published: 2018

Journal Articles

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Asaka Onodera, MDPhD, Keiichi Moriya, MD PhD, Makoto Sasaki, MD PhD, Hiroshi Handa, MD PhDChief Division, Yoichi Imai, MDPhD, Norina Tanaka, MD, Junji Tanaka, MD PhD, Sakae Tanosaki, MDPhD, Shigeki Ito, MD PhD, Norio Komatsu, MD PhD, Koiti Inokuchi, MD PhD

Blood (2017) 130 (Supplement 1): 3055.

https://doi.org/10.1182/blood.V130.Suppl_1.3055.3055

Published: 2017

Journal Articles

Retrospective Analysis of Prognostic Factors for Waldenström Macroglobulinemia: A Multicenter Cooperative Study in Japan

Blood (2015) 126 (23): 5028.

https://doi.org/10.1182/blood.V126.23.5028.5028

Published: 2015

Journal Articles

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Toshio Asayama, MD, Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Yasuko Hamada, MD, Namiko Okuyama, MD, Asaka Onodera, MDPhD, Akiko Yamada, MD, Keiichi Moriya, MD PhD, Norio Yokose, MD PhD, Koiti Inokuchi, PhD MD

Blood (2015) 126 (23): 4117.

https://doi.org/10.1182/blood.V126.23.4117.4117

Published: 2015

Journal Articles

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Akiko Yamada, MD, Hideto Tamura, MD PhD, Mariko Ishibashi, PhD, Koiti Inokuchi, MD PhD, Makoto Sasaki, MD PhD, Yuriko Yahata, MD, Norio Komatsu, MD PhD, Atsushi Isoda, MD PhD, Morio Matsumoto, Hiroshi Handa, MD PhD, Yoichi Imai, MD PhD, Junji Tanaka, MD PhD, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Michiaki Koike, MD PhD

Blood (2014) 124 (21): 2063.

https://doi.org/10.1182/blood.V124.21.2063.2063

Published: 2014

Journal Articles

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Blood (2014) 124 (21): 2018.

https://doi.org/10.1182/blood.V124.21.2018.2018

Published: 2014

Journal Articles

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Noriko Isono, MD, Yoichi Imai, MD PhD, Chihiro Asano, MD, Michihiko Masuda, MD PhD, Shigeru Hoshino, MD PhD, Keiichi Moriya, MD PhD, Hideto Tamura, MD PhD, Koiti Inokuchi, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Toshiko Motoji, MD PhD, Junji Tanaka, MD PhD

Blood (2014) 124 (21): 4411.

https://doi.org/10.1182/blood.V124.21.4411.4411

Published: 2014

Journal Articles

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Shigeki Ito, M.D., Ph.D., Maki Asahi, MD, Ryousei Sasaki, MD, Tatsuo Oyake, M.D., Ph.D., Hideto Tamura, MD, PhD, Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1667.

https://doi.org/10.1182/blood.V122.21.1667.1667

Published: 2013

Journal Articles

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Yasuko Hamada, MD, Mariko Ishibashi, PhD, Toshio Asayama, MD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Hideya Hyodo, MD, PhD, Takehito Igarashi, MD, PhD, Hiroyuki Onose, MD, PhD, Norio Yokose, MD, PhD, Sakae Tanosaki, MD, PhD, Kazuo Shimizu, MD, PhD, Hideto Tamura, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 4320.

https://doi.org/10.1182/blood.V122.21.4320.4320

Published: 2013

Journal Articles

CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients

Yasuko Hamada, MD, Hideto Tamura, MD, PhD, Mariko Ishibashi, PhD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Kiyoyuki Ogata, MD, PhD, Keiji Kakumoto, Yoshihide Miyazaki, Akira Matsuda, MD, PhD, Kaoru Tohyama, MD, PhD, Yasunori Ueda, MD, PhD, Mineo Kurokawa, MD, PhD, Hirohiko Shibayama, Nobuhiko Emi, MD, PhD, Kinuko Mitani, M.D., Ph.D., Tomoki Naoe, MD, PhD, Haruo Sugiyama, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 2799.

https://doi.org/10.1182/blood.V122.21.2799.2799

Published: 2013

Journal Articles

B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior

Hideto Tamura, MD, PhD, Mariko Ishibashi, PhD, Taishi Yamashita, PhD, Asaka Kondo, MD, PhD, Namiko Okuyama, MD, Hideya Hyodo, MD, PhD, Yasuko Hamada, MD, Kazuo Dan, MD, PhD, Lieping Chen, MD, PhD, Kiyoyuki Ogata

Blood (2011) 118 (21): 474.

https://doi.org/10.1182/blood.V118.21.474.474

Published: 2011

Journal Articles

Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes

Asaka Kondo, Taishi Yamashita, Hideto Tamura, Wanhong Zhao, Takashi Tsuji, Masumi Shimizu, Eiji Shinya, Hidemi Takahashi, Koji Tamada, Lieping Chen, Kazuo Dan, Kiyoyuki Ogata

Blood (2010) 116 (7): 1124–1131.

https://doi.org/10.1182/blood-2009-12-255125

Published: 2010

Includes: Supplemental data

Journal Articles

Interferon-γ and Tumor Necrosis Factor-α Induce An Immunoinhibitory Molecule, B7-H1, Via NfκB Activation in Blasts of Myelodysplastic Syndromes.

Asaka Kondo, Hideto Tamura, Taishi Yamashita, Chikako Sato, Zhao Wanhong, Takashi Tsuji, Eiji Shinya, Hidemi Takahashi, Koji Tamada, Lieping Chen, Kazuo Dan, Kiyoyuki Ogata

Blood (2009) 114 (22): 2766.

https://doi.org/10.1182/blood.V114.22.2766.2766

Published: 2009

Journal Articles

Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.

Hideto Tamura, MD, PhD, Kazuo Dan, Norio Yokose, Rika Iwakiri, Masatsugu Ohta, Hisashi Sakamaki, Kaoru Tohyama, Kondo Asaka, Hideya Hyodo, Kyoko Nakamura, Taishi Yamashita, Olga A Elisseeva, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama, Kiyoyuki Ogata

Blood (2009) 114 (22): 3821.

https://doi.org/10.1182/blood.V114.22.3821.3821

Published: 2009

Journal Articles

Expression and Function of B7.2 and B7-H2 Molecules on Myeloma Cells

Taishi Yamashita, Hideto Tamura, MD, PhD, Chikako Sato, Asaka Kondo, Eiji Shinya, Hidemi Takahashi, Lieping Chen, Takashi Tsuji, Kazuo Dan, Kiyoyuki Ogata, MD, PhD

Blood (2008) 112 (11): 2722.

https://doi.org/10.1182/blood.V112.11.2722.2722

Published: 2008

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Elucidating the Role of Tolerogenic Dendritic Cells in Immune Tolerance and Disease Progression in Multiple Myeloma

DNAM-1/Tigit/CD155/CD112 Axis Is a Novel Target of NK-Cell Therapy in Acute Myeloid Leukemia

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Retrospective Analysis of Prognostic Factors for Waldenström Macroglobulinemia: A Multicenter Cooperative Study in Japan

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients

B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior

Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes

Interferon-γ and Tumor Necrosis Factor-α Induce An Immunoinhibitory Molecule, B7-H1, Via NfκB Activation in Blasts of Myelodysplastic Syndromes.

Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.

Expression and Function of B7.2 and B7-H2 Molecules on Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only